EP3429584A4 - Compositions and methods for the treatment of presbyopia - Google Patents

Compositions and methods for the treatment of presbyopia Download PDF

Info

Publication number
EP3429584A4
EP3429584A4 EP17767172.4A EP17767172A EP3429584A4 EP 3429584 A4 EP3429584 A4 EP 3429584A4 EP 17767172 A EP17767172 A EP 17767172A EP 3429584 A4 EP3429584 A4 EP 3429584A4
Authority
EP
European Patent Office
Prior art keywords
presbyopia
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17767172.4A
Other languages
German (de)
French (fr)
Other versions
EP3429584A1 (en
Inventor
Gerald Horn
Lee NORDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presbyopia Therapies Inc
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/073,089 external-priority patent/US9844537B2/en
Priority claimed from US15/073,139 external-priority patent/US9833441B2/en
Priority claimed from US15/235,431 external-priority patent/US10052313B2/en
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of EP3429584A1 publication Critical patent/EP3429584A1/en
Publication of EP3429584A4 publication Critical patent/EP3429584A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP17767172.4A 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia Withdrawn EP3429584A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/073,089 US9844537B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,139 US9833441B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/235,431 US10052313B2 (en) 2013-08-28 2016-08-12 Compositions and methods for the treatment of presbyopia
PCT/US2017/021244 WO2017160548A1 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Publications (2)

Publication Number Publication Date
EP3429584A1 EP3429584A1 (en) 2019-01-23
EP3429584A4 true EP3429584A4 (en) 2019-11-13

Family

ID=59852351

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17767172.4A Withdrawn EP3429584A4 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Country Status (6)

Country Link
EP (1) EP3429584A4 (en)
JP (1) JP2019508472A (en)
CN (1) CN108883102A (en)
CA (1) CA3017755A1 (en)
MX (1) MX2018011300A (en)
WO (1) WO2017160548A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147535A2 (en) * 2018-01-24 2019-08-01 Eye Therapies, Llc Methods for improving vision
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
MX2021004183A (en) * 2018-10-10 2021-10-26 Presbyopia Therapies Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA.
EP4003341A4 (en) * 2019-07-26 2023-08-30 Allergan Sales, LLC Compositions and methods for treatment of presbyopia
CN116583277A (en) * 2020-11-02 2023-08-11 视觉治疗股份有限公司 Degrading Compounds in Drugs
EP4736853A2 (en) * 2020-11-02 2026-05-06 Visus Therapeutics, Inc. Degradant compound in a medicament
EP4429652A4 (en) 2021-11-10 2025-09-10 Visus Therapeutics Inc CARBAACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECT
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN114588156B (en) * 2022-04-22 2024-06-11 温州医科大学附属眼视光医院 Ophthalmic preparation and application thereof in treating presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008278A1 (en) * 2013-08-28 2016-01-14 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) * 2013-08-28 2016-12-01 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
JP2017501224A (en) * 2013-12-18 2017-01-12 ジー・エヌ・ティー・エル・エル・シー Compositions and methods for the treatment of glaucoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008278A1 (en) * 2013-08-28 2016-01-14 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) * 2013-08-28 2016-12-01 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017160548A1 *

Also Published As

Publication number Publication date
CA3017755A1 (en) 2017-09-21
CN108883102A (en) 2018-11-23
EP3429584A1 (en) 2019-01-23
JP2019508472A (en) 2019-03-28
MX2018011300A (en) 2019-02-18
WO2017160548A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3863630A4 (en) Compositions and methods for the treatment of presbyopia
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
EP3687524A4 (en) Compositions and methods for treating ophthalmic conditions
EP3094284A4 (en) Compositions and methods for the treatment of intraocular neovascularization and/or leakage
EP3720421A4 (en) Compositions and methods for the treatment of metabolic conditions
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
IL272121A (en) Composition and methods for the treatment of myopia
EP3265096A4 (en) Ophthalmic compositions and methods of use therefor
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
EP3310783A4 (en) Methods and compositions for the prevention and treatment of hearing loss
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3491129A4 (en) Methods of treating osmidrosis
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3107534A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
ZA201900984B (en) Methods and compositions for the treatment of warts
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3206708A4 (en) Methods and compositions for the treatment of radiation-related disorders
IL282455A (en) Methods and compositions for the treatment of secretory disorders
EP3280406A4 (en) Compositions and methods for treatment of movement disorders
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
HK40031097A (en) Composition and methods for the treatment of myopia
HK40038038A (en) Methods of treatment of hypertrigl yceridemia

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/439 20060101AFI20191004BHEP

Ipc: A61K 47/38 20060101ALI20191004BHEP

Ipc: A61P 27/10 20060101ALI20191004BHEP

Ipc: A61K 9/00 20060101ALI20191004BHEP

Ipc: A61K 31/4409 20060101ALI20191004BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603